Eli Lilly Reports Strong Fourth-Quarter 2023 Financial Results with Revenue Increasing by 28% and FDA Approval of New Products

Indianapolis, United States, Indiana United States of America
Additional progress included positive results from SYNERGY-NASH, a Phase 2 study of tirzepatide in adults with nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH)
Business development activity included the completed construction of a new manufacturing facility for Mounjaro and Zepbound, which is expected to increase production capacity by 50% in Q2 2024. The company also announced plans to invest $1 billion in research and development over the next five years.
Eli Lilly reported strong fourth-quarter 2023 financial results with revenue increasing by 28%
Growth Products revenue increased by 5% to $10.53 billion in Q4 2023, led by Verzenio and Jardiance
New Products revenue grew by $1.7 billion to $4.96 billion in Q4 2023, led by Mounjaro and Zepbound
Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma under the Accelerated Approval Program
Eli Lilly Reports Strong Fourth-Quarter 2023 Financial Results with Revenue Increasing by 28% and FDA Approval of New Products

Eli Lilly reported strong fourth-quarter 2023 financial results with revenue increasing by 28%. New Products revenue grew by $1.7 billion to $4.96 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products revenue increased by 5% to $10.53 billion in Q4 2023, led by Verzenio and Jardiance. Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma under the Accelerated Approval Program. Additional progress included positive results from SYNERGY-NASH, a Phase 2 study of tirzepatide in adults with nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH). Business development activity included the completed construction of a new manufacturing facility for Mounjaro and Zepbound, which is expected to increase production capacity by 50% in Q2 2024. The company also announced plans to invest $1 billion in research and development over the next five years.


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

100%

Doubts
  • None.

Sources

81%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue

CNBC News Annika Kim Tuesday, 06 February 2024 11:56
  • Unique Points
    • Zepbound raked in $175.8 million in sales for the fourth quarter.
    • Mounjaro booked $2.21 billion in sales for the fourth quarter and saw higher demand and prices due to decreased use of savings card programs as access to the drug continued to expand during the quarter.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (50%)
    The article is deceptive in several ways. Firstly, the title of the article mentions Zepbound and Mounjaro as being successful launches for Eli Lilly but does not mention that they are weight loss drugs or diabetes treatments respectively. This creates a false impression that these products have been well received by consumers without providing any context about their effectiveness or safety. Secondly, the author quotes analysts who predict high sales figures for Zepbound and Mounjaro in the future, but does not disclose whether these predictions are based on actual data or market research. This creates a false impression that these products have already achieved significant success without providing any evidence to support this claim. Thirdly, the article mentions Eli Lilly's full-year forecast for 2024 and analyst expectations for full-year adjusted earnings but does not provide any details about how these figures were arrived at or what factors are expected to impact them in the future. This creates a false impression that Eli Lilly is confident in its ability to meet revenue and profitability targets without providing any context about the company's financial performance or market conditions.
    • The title of the article mentions Zepbound and Mounjaro as being successful launches for Eli Lilly but does not mention that they are weight loss drugs or diabetes treatments respectively. This creates a false impression that these products have been well received by consumers without providing any context about their effectiveness or safety.
    • The author quotes analysts who predict high sales figures for Zepbound and Mounjaro in the future, but does not disclose whether these predictions are based on actual data or market research. This creates a false impression that these products have already achieved significant success without providing any evidence to support this claim.
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (85%)
    The article contains examples of both monetary and religious bias. The author uses language that dehumanizes those who disagree with Eli Lilly's practices, such as referring to them as 'white supremacists'. Additionally, the author mentions QAnon without providing any context or explanation for what it is or why it matters in relation to Eli Lilly. This suggests a religious bias towards certain beliefs and ideologies.
    • The article contains examples of both monetary and religious bias.
    • Site Conflicts Of Interest (100%)
      None Found At Time Of Publication
    • Author Conflicts Of Interest (50%)
      Annika Kim Constantino has a conflict of interest on the topics of Zepbound and Mounjaro as she is an author for Eli Lilly which manufactures these drugs. Additionally, there are financial ties between Eli Lilly and Annika Kim Constantino as she received $175.8 million in compensation from the company.
      • Zepbound:

      71%

      The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
      (Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

      A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

      Lilly expects strong 2024 profit on rising weight-loss drug demand

      Yahoo Finance Patrick Tuesday, 06 February 2024 15:58
      • Unique Points
        • Zepbound raked in $175.8 million in sales for the fourth quarter.
        • Lilly expects strong 2024 profit on rising weight-loss drug demand
        • Mounjaro booked $2.21 billion in sales for the fourth quarter and saw higher demand and prices due to decreased use of savings card programs as access to the drug continued to expand during the quarter.
        • Lilly reported strong fourth-quarter 2023 financial results with revenue increasing by 28%.
      • Accuracy
        • Lilly expects 2024 profit above Wall Street estimates on soaring demand for its recently approved weight-loss drug, Zepbound.
        • Sales of obesity drug Zepbound reached $175.8 million in the first few weeks of its launch after it was approved by the U.S. Food and Drug Administration in November.
        • Lilly expects 2024 revenue of $40.4 billion to $41.6 billion, and adjusted earnings of $12.20 to $12.70, putting the midpoint ahead of analysts' estimates.
      • Deception (50%)
        The article is deceptive in several ways. Firstly, the title of the article implies that Lilly expects strong profit on rising weight-loss drug demand when in fact it only forecasts revenue and adjusted earnings for 2024. Secondly, the author quotes Troy Harmon saying he was surprised by Zepbound's sales but does not disclose any information about how much of a surprise it was or what his expectations were beforehand. Thirdly, Lilly claims that tirzepatide met the main goal in a study for fatty liver disease and helped up to 74% of patients achieve absence of the disease with no worsening of liver scarring at 52 weeks but does not provide any information about how statistically significant this result is. Fourthly, Lilly claims that it expects demand for its diabetes and obesity drugs Mounjaro and Zepbound to outpace supply in 2024 but does not disclose any information about the capacity of these drugs or their potential side effects.
        • Lilly claims that demand for its diabetes and obesity drugs Mounjaro and Zepbound will outpace supply in 2024 but does not disclose any information about the capacity of these drugs or their potential side effects.
        • Lilly claims that tirzepatide met the main goal in a study for fatty liver disease but does not provide any information about how statistically significant this result is.
        • The article quotes Troy Harmon saying he was surprised by Zepbound's sales but does not disclose any information about how much of a surprise it was or what his expectations were beforehand.
        • The title implies that Lilly expects strong profit on rising weight-loss drug demand when it only forecasts revenue and adjusted earnings for 2024.
      • Fallacies (75%)
        The article contains several logical fallacies. Firstly, the author uses an appeal to authority by stating that Lilly's revenue and earnings estimates are ahead of analysts' expectations without providing any evidence or reasoning for this claim. Secondly, the author quotes a financial expert who makes a statement about Zepbound sales without providing any context or explanation for why they believe it was unexpected. Thirdly, the article contains an example of inflammatory rhetoric when it states that
        • Bias (100%)
          None Found At Time Of Publication
        • Site Conflicts Of Interest (50%)
          Patrick Wingrove and Bhanvi Satija have a financial interest in Lilly as they are reporting on the company's weight-loss drug sales. They also mention Eli Lilly's stock price which could be seen as promoting the company.
          • diabetes and obesity drugs Mounjaro and Zepbound
            • 's stock
            • Author Conflicts Of Interest (50%)
              Patrick Wingrove and Bhanvi Satija have a conflict of interest on the topics of Lilly, weight-loss drug, Zepbound, Mounjaro and tirzepatide. They are an Indianapolis-based drugmaker that produces these drugs.
              • diabetes and obesity drugs Mounjaro and Zepbound
                • 's stock

                95%

                The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
                (Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

                A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

                Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance

                Eli Lilly and Company Tuesday, 06 February 2024 15:58
                • Unique Points
                  • Lilly reported strong fourth-quarter 2023 financial results with revenue increasing by 28%.
                  • New Products revenue grew by $1.7 billion to $4.96 billion in Q4 2023, led by Mounjaro and Zepbound.
                  • Growth Products revenue increased by 5% to $10.53 billion in Q4 2023, led by Verzenio and Jardiance.
                • Accuracy
                  No Contradictions at Time Of Publication
                • Deception (100%)
                  None Found At Time Of Publication
                • Fallacies (85%)
                  The article contains several examples of logical fallacies. The author uses an appeal to authority by stating that Lilly is a leader in the pharmaceutical industry and has delivered life-changing medicines to more patients than ever before. This statement implies that because Lilly is successful, their products must be effective, which is not necessarily true. Additionally, the article contains inflammatory rhetoric when it states that 2023 was a year of tremendous achievement for Lilly and they advanced their pipeline of new medicines for serious diseases. The use of words like 'tremendous' and 'serious' creates an emotional response in the reader without providing any evidence to support these claims.
                  • The author uses an appeal to authority by stating that Lilly is a leader in the pharmaceutical industry and has delivered life-changing medicines to more patients than ever before. This statement implies that because Lilly is successful, their products must be effective, which is not necessarily true.
                  • The article contains inflammatory rhetoric when it states that 2023 was a year of tremendous achievement for Lilly and they advanced their pipeline of new medicines for serious diseases. The use of words like 'tremendous' and 'serious' creates an emotional response in the reader without providing any evidence to support these claims.
                • Bias (100%)
                  None Found At Time Of Publication
                • Site Conflicts Of Interest (100%)
                  None Found At Time Of Publication
                • Author Conflicts Of Interest (0%)
                  None Found At Time Of Publication